Developing T cell cancer immunotherapy in the dog with lymphoma

ILAR Journal

Volumn 55, Issue 1, 2014, Pages 169-181

  O'Connor, Colleen M ^a   Wilson Robles, Heather ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Adoptive T cell therapy; Canine; Chimeric antigen receptor; Lymphoma; T cell receptor

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; DISEASE MODEL; DOG; DOG DISEASES; GENETICS; IMMUNOLOGY; LYMPHOMA, B-CELL; NONHODGKIN LYMPHOMA; PET ANIMAL; PROCEDURES; PROTEIN ENGINEERING; T LYMPHOCYTE; TRENDS; VETERINARY;

ANIMALS; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; PETS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN; T-LYMPHOCYTES;

EID: 84902466816     PISSN: 10842020     EISSN: 19306180     Source Type: Journal    
DOI: 10.1093/ilar/ilu020     Document Type: Article

References (137)

1. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. 2008. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14:5220-5227.
2. Andersen BM, Pluhar G, Seiler CE, Goulart MR, SantaCruz KS, Schutten MM, Meints JP, O'Sullivan MG, Bentley RT, Packer RA, Thomovsky SA, Chen AV, Faissler D, Chen W, Hunt MA, Olin MR, Ohlfest JR. 2013. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cellmediated cytotoxicity. Cancer Res 73:2987-2997.
3. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25:705-708.
4. Aquino A, Formica V, Prete SP, Correale PP, Massara MC, Turriziani M, De Vecchis L, Bonmassar E. 2004. Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 49:383-396.
5. Back AR, Schleis SE, Smrkovski OA, Lee J, Smith AN, Phillips JC. 2013. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. Vet Comp Oncol. doi: 10.1111/vco.12055. Epub 2013 Aug 5.
6. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. 2013. Regimenspecific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 24:717-727.
7. Bassig BA, Lan Q, Rothman N, Zhang Y, Zheng T. 2013. Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: An epidemiological update. J Cancer 24:287-295.
8. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G. 2006. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for surviva. Cancer Immunol Immunother 55:684-698.
9. Beyer M, Schultze JL. 2009. Regulatory T cells: Major players in the tumor microenvironment. Curr Pharm Des 15:1879-1892.
10. Biller BJ, Guth A, Burton JH, Dow SW. 2010. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med 24:1118-1123.
11. Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C. 2013. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 163:393-399.
12. Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, Dickson MC, Leandro MJ, Edwards JC. 2014. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun. 50:67-76.
13. Carter RF, Valli VE, Lumsden JH. 1986. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer InstituteWorking Formulation. Can J Vet Res 50:154-164.
14. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM. 1993. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225-1230.
15. Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA. 2011. ATCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 186:685-696.
16. Christensson B, Lindemalm C, Johansson B, Mellstedt H, Ost A, Biberfeld P. 1983. Correlation of immunophenotype to morphology in unfavourable non-Hodgkin lymphoma. Acta Pathol Microbiol Immunol Scand A 91:425-433.
17. Chun R, Garrett LD, Vail DM. 2000. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 14:120-124.
18. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163:507-513.
19. Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA. 2005. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol 175:5799-5808.
20. Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, Van Gool SW. 2013. Wilms' tumor gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: A phase I/II clinical trial. Anticancer Res 33:5495-5500.
21. Daters AT, Mauldin GE, Mauldin GN, Brodsky EM, Post GS. 2010. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma. Vet Comp Oncol 8:11-22.
22. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. 2008. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: Implications for risk stratification and future studies. Cancer 112:407-415.
23. De Costa AM, Schuyler CA, Walker DD, Young MR. 2012. Characterization of the evoluntion of immune phenotype during the development and progression of squamous cell carcinoma of the headn and neck. Cancer Immunol Immunother 61:927-939.
24. Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. 2013. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One 8:e77719.
25. Declerck S, Vansteenkiste J. 2014. Immunotherapy for lung cancer: ongoing clinical trials. Future Oncol 10:91-105.
26. Denies S, Sanders N. 2012. Recent progress in canine tumor vaccination: potential applications for human tumor vaccines. Expert Rev Vaccines 11:1375-1386.
27. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ. 2013. Bispecific T cells expressing polyclonal repertoire of endogenous γδ T cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 21:638-647.
28. Dudley ME. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854.
29. Eljaszewicz A, Wiese M, Helmin-Basa A, Jankowski M, Gackowska L, Kubiszewska I, Kaszewski W, Michalkiewicz J, Zegarski W. 2013. Collaborating with the enemy: Function of macrophages in the development of neoplastic disease. Mediators Inflamm 2013:831387.
30. Essand M, Loskog A. 2013. Genetically engineered T cells for the treatment of cancer. J Intern Med 273:166-181.
31. Estrela-Lima A, Araújo MS, Costa-Neto JM, Teixeira-Carvalho A, Barrouin-Melo SM, Cardoso SV, Martins-Filho OA, Serakides R, Cassali GD. 2010. Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 10:256.
32. Fahey CE, Milner RJ, Barabas K, Lurie D, Kow K, Parfitt S, Lyles S, Clemente M. 2011. Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). J Am Vet Med Assoc 239:209-215.
33. Falkenburg WJJ, Melenhorst JJ, van de Meent M, Kester MGD, Hombrink P, HeemskerkMHM, Hagedoorn RS, Gostick E, Price DA, Falkenburg JHF, et al. 2011. Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity. J Immunol 187:2824-2833.
34. Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, Abrams SI, Lee KP. 2014. Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance. Sci Signal 7:ra16.
35. Ferreira LM. 2013. Gammadelta T cells: Innately adaptive immune cells? Int Rev Immunol 32:223-248.
36. Flory AB, Rassnick KM, Al-Sarraf R, Bailey DB, Balkman CE, Kiselow MA, Autio K. 2008. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med 22:164-171.
37. Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA. 2010. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol. 184:5988-5998.
38. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F. 2002. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169-178.
39. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964.
40. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. 2006. Adoptive immunotherapy for cancer: Building on success. Nature Rev Immunol 6:383-393.
41. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L. 2013. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther 24:728-738.
42. Graves SS, Mathes DW, Georges GE, Kuhr CS, Chang J, Butts TM, Storb R. 2012. Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model. Transplantation 94:562-568.
43. Greenberg PD, Reusser P, Goodrich JM, Riddell SR. 1991. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMVspecific T cell clones expanded in vitro. Ann N YAcad Sci 636:184-195.
44. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD. 2011. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72:1631-1638.
45. Hackett PB, Largaespada DA, Cooper LJ. 2010. A transposon and transposase system for human application. Mol Ther 18:674-683.
46. Henry CJ, Downing S, Rosenthal RC, Klein MK, Meleo K, Villamil JA, Fineman LS, McCaw DL, Higginbotham ML, McMichael J. 2007. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res 68:1246-1251.
47. Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M. 2012. T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc Natl Acad Sci U S A 109:15877-15881.
48. Hinrichs CS, Gattinoni L, Restifo NP. 2006. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 18:363-370.
49. Hoyt R, Ritchie DS, Roberts AW, Macgregor L, Curtis DJ, Szer J, Grigg AP. 2008. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Bone Marrow Transplant 41:651-658.
50. Impellizeri JA, Howell K, McKeever KP, Crow SE. 2006. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. Vet J 171:556-558.
51. Ito D, Endicott M, Jubala CM, Helm KM, Burnett RC, Husbands BD, Borgatti A, Henson MS, Burgess KE, Bell JS, Kisseberth WC, Valli VE, Cutter GR, Avery AC, Hahn KA, O'Brien TD, Modiano JF. 2011. A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. J Vet Intern Med 25:890-896.
52. Jarnicki AG, Lysaght J, Todryk S, Mills KH. 2006. Suppression of antitumor immunity by IL-10 and TGF-beta-producing Tcells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177:896-904.
53. Jena B, Dotti G, Cooper LJN. 2010. Redirecting T cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116:1035-1044.
54. Johnson LA, Heemskirk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA. 2006. Gene transfer of tumorreactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177:6548-6559.
55. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. 2009. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546.
56. Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Fosmire SP, Coffey D, Bellgrau D, Modiano JF. 2005. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol 42:468-476.
57. Kaiser HE. 1981. Animal Neoplasms: A Systematic Review. Baltimore MD: Williams and Wilkins.
58. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73.
59. Kaneno R, Shurin GV, Kaneno FM, Naiditch H, Luo J, Shurin MR. 2011. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol 34:97-106.
60. Klebanoff CA, Gattinoni L, Restifo NP. 2006. CD8+ T cell memory in tumor immunology and immunotherapy. Immunol Rev 211:214-224.
61. Kuhr CS, Allen MD, Junghanss C, Zaucha JM, Marsh CL, Yunusov M, Zellme E, Little MT, Torok-Storb B, Storb R. 2002. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 73:1487-1492.
62. Kuhr CS, Yunusov M, Sale G, Loretz C, Storb R. 2007. Long-term tolerance to kidney allografts in a preclinical canine model. Transplantation 84:545-547.
63. Lee SB, Haber DA. 2001. Wilms tumor and the WT1 gene. Exp Cell Res 264:74-99.
64. Lenschow DJ, Walunas TL, Bluestone JA. 1996. CD28/B7 system of T cell co-stimulation. Annu Rev Immunol 14:233-258.
65. Li Y, Bleakley M, Yee C. 2005. IL-21 Influences the frequency, phenotype, and affinity of the antigen specific CD8 T cell response. J Immunol 175:2261-2269.
66. Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. 2006. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6.
67. Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A. 2013. Mortality in rheumatoid arthritis: The impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204021.
68. Lupu M, Sullivan EW, Westfall TE, Little MT, Weigler BJ, Moore PF, Stroup PA, Zellmer E, Kuhr C, Storb R. 2006. Use of multigenerationfamily molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T cell lymphoma. J Am Vet Med Assoc 228:728-732.
69. Mackall CL, Fry TJ, Gress RE. 2011. Harnessing the biology of IL-7 for therapeutic application. Nature Rev Immunol 11:330-342.
70. Malhotra D, Fletcher AL, Turley SJ. 2013. Stromal and hematopoietic cells in secondary lymphoid organs: Partners in immunity. Immunol Rev 251:160-176.
71. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195.
72. Maus MV, Grupp SA, Porter DL, June CH. 2014. Antibody modified Tcells: CARs take the front seat for hematologic malignancies. Blood 123:2625-2635.
73. McLaughlin P, White CA, Grillo-López AJ, Maloney DG. 1998. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12:1763-1769.
74. Meyer JA, Dueland RT, MacEwen EG, Macy DW, Hoefle WD, Richardson RC, Alexander JW, Trotter E, Hause WR. 1982. Canine osteogenic sarcoma treated by amputation and MER: an adverse effect of splenectomy on survival. Cancer 49:1613-1616.
75. Michishita M, Uto T, Nakazawa R, Yoshimura H, Ogihara K, Naya Y, Tajima T, Azakam ID, Kishikawa S, Arai T, Takahashi K. 2013. Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma. J Pharmacol Sci 121:339-342.
76. Milner RJ, Salute M, Crawford C, Abbot JR, Farese J. 2006. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Vet Immunol Immunopathol 114:273-284.
77. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH. 2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of Tcells and increased antileukemic efficacy in vivo. Mol Ther 17:1453-1464.
78. Mitchell L, Dow SW, Slansky JE, Biller BJ. 2012. Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. Vet Immunol Immunopathol 145:597-603.
79. Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, Avery PR, Lindblad-Toh K, Ostrander EA, Cutter GC, Avery AC. 2005. Distinct B-cell and T cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 65:5654-5661.
80. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 6:126-129.
81. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA. 2003. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171:3287-3295.
82. Mortimer J, Zonder HB, Pal SK. 2012. Lessons learned from the bevacizumab experience. Cancer Control 19:309-316.
83. Moulton JE, Harvey JW. 1990. Tumors of Lymphoid and Hematopoietic Tissue. Berkeley: University of California Press.
84. Mukaratirwa S, Chitanga S, Chimatira T, Makuleke C, Sayi ST, Bhebhe E. 2009. Combination therapy using intratumoral bacillus Calmette-Guerin (BCG) and vincristine in dogs with transmissible venereal tumours: Therapeutic efficacy and histological changes. J S Afr Vet Assoc 80:92-96.
85. Narita Y, Kitamura H, Wakita D, Sumida K, Masuko K, Terada S, Nakano K, Nishimura T. 2013. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol 190:812-820.
86. Niemeyer GP, Welch JA, Tillson M, Brawner W, Rynders P, Goodman S, Dufresne M, Dennis J, Lothrop CD Jr. 2005. Renal allograft tolerance in DLA-identical and haploidentical dogs after nonmyeloablative conditioning and transient immunosuppression with cyclosporine and mycophenolate mofetil. Transplant Proc 37:4579-4586.
87. O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, et al. 2012. Adoptive T cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep 2:249.
88. Ott PA, Hodi FS, Robert C. 2013. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300-5309.
89. Ottnod JM, Smedley RC, Walshaw R, Hauptman JG, Kiupel M, Obradovich JE. 2013. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol 11:219-229.
90. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. 2005. Effector memory Tcells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666.
91. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. 2010. Immune filtration in human tumors: A prognostic factor that should not be ignored. Oncogene 29:1093-1102.
92. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G, et al. 1993. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nature 4:415-420.
93. Parker MH, Kuhr C, Tapscott SJ, Storb R. 2008. Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs. Mol Ther 16:1340-1346.
94. Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA. 2009. Characterization of genetically modified T cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 15:169-180.
95. Parodi AL, Misdorp W, Mialot JP, Mialot M, Hart AA, Hurtrel M, Salomon JC. 1983. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother 15:172-177.
96. Paulos CM. 2007. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. 117:2197-2204.
97. Peggs KS, Segal NH, Allison JP. 2007. Targeting immunosupportive cancer therapies: Accentuate the positive, eliminate the negative. Cancer Cell 12:192-199.
98. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. 2007. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67:354-361.
99. Porrata LF, Inwards D, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Litzow MR, Winters JL, Markovic SN. 2008. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study. Biol Blood Marrow Transplant 14:807-816.
100. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733.
101. Qeska V, Baumgartner W, Beineke A. 2013. Species-specific properties and translational aspects of canine dendritic cells. Vet Immunol Immunopathol 151:181-192.
102. Rabinovich GA, Gabrilovich D, Sotomayor EM. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296.
103. Ruella M, Kalos M. 2014. Adoptive immunotherapy for cancer. Immunol Rev 257:14-38.
104. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. 2000. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: A prospective randomized study. Blood 96:2391-2398.
105. Sánchez-Ramón S, Eguíluz-Gracia I, Rodríguez-Mazariego ME, Paravisini A, Zubeldia-Ortuño JM, Gil-Herrera J, Fernández-Cruz E, Suárez-Fernández R. 2013. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Invest Allergol Clin Immunol 23:190-196.
106. Schaft N, Willemsen R, de Vries J, Lankiewicz B, Essers BW, Gratama JW, Figdor CG, Bolhuis RL, Debets R, Adema GJ. 2003. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 170:2186-2194.
107. Scharf VF, Farese JP, Coomer AR, Milner RJ, Taylor DP, Salute ME, Chang MN, Neal D, Siemann DW. 2013. Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. Am J Vet Res 74:771-778.
108. Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD. 2013. Enhanced-affinity murine T cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood 122:348-356.
109. Schmitt TM, Ragnarsson GB, Greenberg PD. 2009. Tcell receptor gene therapy for cancer. Hum Gene Ther 20:1240-1248.
110. Scott AM, Allison JP, Wolchok JD. 2012. Monoclonal antibodies in cancer therapy. Cancer Immun 12.
111. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. 2010. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 5:585-590.
112. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. 2009. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183:137-144.
113. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Call TG, Porrata LF. 2006. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134:596-601.
114. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. 2011. Reprogramming CD19-specific Tcells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71:3516-3527.
115. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. 2013. Manufacture of clinical-grade CD19-specific T Cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 8:e64138.
116. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. 2008. Redirecting specificity of T cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68:2961-2971.
117. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ. 2011. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One 6:e24167.
118. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief CJ, Huber C, Stauss HJ, Theobald M. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2:962-970.
119. Stephan MT. 2007. T cell-encoded CD80 and 4-1BBL induce auto-and transcostimulation, resulting in potent tumor rejection. Nature Med 13:1440-1449.
120. Straetemans T, van Brakel M, van Steenbergen S, Broertjes M, Drexhage J, Hegmans J, Lambrecht BN, Lamers C, van Der Bruggen P, Coulie PG, Debets R. 2012. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol 2012.
121. Tobinai K, Ogura M, Kuniaki I, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y. 2010. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7 year follow-up results. Cancer Sci 101:2579-2585.
122. Tongu M, Harashima N, Yamada T, Harada T, Harada M. 2010. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 59:769-777.
123. Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, Morris EC. 2014. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 164:366-375.
124. Vail DM, Young KM. 2007. Canine Lymphoma and Lymphoid Leukemia. St. Louis MO: Saunders Elsevier.
125. Valerius KD, Ogilvie GK, Mallinckrodt CH, Getzy DM. 1997. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 210:512-516.
126. Valli VE, Kass PH, San Myint M, Scott F. 2013. Canine lymphomas: Association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. Vet Pathol 50:738-748.
127. Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F, Durham A, Ehrhart EJ, Johnson Y, Jones C, Kiupel M, Labelle P, Lester S, Miller M, Moore P, Moroff S, Roccabianca P, Ramos-Vara J, Ross A, Scase T, Tvedten H, Vernau W. 2010. Classification of canine malignant lymphomas according to theWorld Health Organization criteria. Vet Pathol 48:198-211.
128. Varilla V, Atienza J, Dasanu CA. 2013. Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther 13:1241-1256.
129. Vose J. 2005. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: A promising approach. Clin Adv Hematol Oncol 3:923-932.
130. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. 2005. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leukemia Lymphoma 46: 1569-1573.
131. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. 2004. Myelodysplasiaassociated autoimmunity: Clinical and pathophysiologic concepts. Eur J Clin Invest 34:690-700.
132. Voulgarelis V, Giannouli S, Anagnostou D, Tzioufas AG. 2004. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology 43:1050-1053.
133. Watabe A, Fukumoto S, Komatsu T, Endo Y, Kadosawa T. 2011. Alterations of lymphocyte subpopulations in healthy dogs with aging and in dogs with cancer. Vet Immunol Immunopathol 142:189-200.
134. Willcox JL, Pruitt A, Suter SE. 2012. Autologous peripheral blood hematopoietic cell transplantation in dogs with B-cell lymphoma. J Vet Intern Med 26:1155-1163.
135. Wrzesinski C. 2010. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33:1-7.
136. Wrzesinski C, Restifo NP. 2005. Less is more: Lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T cell-based antitumor immunotherapy. Curr Opin Immunol 17:195-201.
137. Zandvliet M, Rutteman GR, Teske E. 2013. Prednisolone inclusion in a firstline multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results. Vet J 197:656-661.